Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | aspartyl/glutamyl-tRNA amidotransferase subunit A | 0.0064 | 0 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0365 | 0.641 | 0.5 |
Brugia malayi | hypothetical protein | 0.0286 | 0.4719 | 0.4719 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0533 | 1 | 1 |
Mycobacterium ulcerans | lysophospholipase | 0.0365 | 0.641 | 1 |
Chlamydia trachomatis | glutamyl-tRNA(Gln) amidotransferase subunit A | 0.0064 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0533 | 1 | 1 |
Plasmodium falciparum | lysophospholipase, putative | 0.0365 | 0.641 | 1 |
Mycobacterium tuberculosis | Possible lysophospholipase | 0.0365 | 0.641 | 1 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0365 | 0.641 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.4719 | 0.4719 |
Plasmodium falciparum | lysophospholipase, putative | 0.0365 | 0.641 | 1 |
Trypanosoma cruzi | monoglyceride lipase, putative | 0.0365 | 0.641 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0365 | 0.641 | 0.5 |
Plasmodium vivax | PST-A protein | 0.0365 | 0.641 | 1 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0365 | 0.641 | 0.5 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.4719 | 0.4719 |
Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.0365 | 0.641 | 0.5 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0533 | 1 | 1 |
Plasmodium falciparum | esterase, putative | 0.0365 | 0.641 | 1 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0533 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0365 | 0.641 | 0.5 |
Treponema pallidum | aspartyl/glutamyl-tRNA amidotransferase subunit A | 0.0064 | 0 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0365 | 0.641 | 1 |
Leishmania major | monoglyceride lipase, putative | 0.0365 | 0.641 | 1 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0365 | 0.641 | 0.5 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0365 | 0.641 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0533 | 1 | 1 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0365 | 0.641 | 1 |
Schistosoma mansoni | amidase | 0.0533 | 1 | 1 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0533 | 1 | 1 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0365 | 0.641 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.0365 | 0.641 | 1 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.4719 | 0.4719 |
Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.0365 | 0.641 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0365 | 0.641 | 1 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0365 | 0.641 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0316 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.6573 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Relaxin Receptor RXFP1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF. (Class of assay: confirmatory) [Related pubchem assays: 995 ] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 84.9214 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.